English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Rismaya, Azamris, Budiarti S, Desriani. 2017. Housekeeping gene as a source of calibrator candidate for HER-2 scoring in frozen tissue breast cancer study based on qPCR. Biodiversitas 18: 1041-1046. HER-2 amplification in breast cancer gives an implication in therapy and prognosis. FDA have been approved Fluorescence In situ hybridization (FISH) for HER-2 amplification and immunohistochemistry (IHC) for protein expression measurement. In this recently times, quantitative PCR techniques have been reported as an alternative method for HER-2 amplification determination. Here in this report, we investigated new reference gene coming from housekeeping gene as an alternative calibrator for HER-2 amplification scoring based on qPCR methods. We compared two recommended housekeeping gene, 18S rRNA and β-Actin, as a candidate for a HER-2 calibrator. For methods development, optimization and comparison study between 18S rRNA and β-Actin, we used non-invasive samples (DNA buccal cells). Selected candidate reference further was tested to eighteen breast cancer sample, validated with qPCR methods refer to Mendoza et al. 2013. β- Actin is shown as the best candidate for HER-2 scoring status determination. qPCR concordance result with other qPCR methods refers to Mendoza et al. 2013 shown 94.4%. The qPCR efficiency and % CV value shown as a requirement as a theory. qPCR efficiency was 103.8-105.3% for β-Actin and HER-2 respectively while CV value was around 1.2%. Our result showed a significant correlation with reported methods, which could potentially complement with FDA approved methods.